Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma

Figures & data

Table 1. Cliniopathological parameters in Her2-neu positive and negative gastric adenocarcinoma (n = 50).

	Age (years)			Gender		Tumor site		Tumor type		Tumor grade		Lymphovascular invasion		Neural invasion
Her 2 neu status	> 39	40–50	<50	M	F	Proximal	Distal	Diffuse	Intestinal	Low (Well – Mod)	High (Poor	+ve	-ve	+ve	-ve
Positive	-	6	-	6		5	1	-	6	5-Mod	1	4	2	3	3
% age (n = 6)	0	100	0	100	0	83	17	0	100	83	17	67	33	50	50
Negative	-	16	28	29	15	20	24	23	21	15	29	18	26	16	28
% age (n = 44)	0	36	64	66	34	45	55	52	48	34	66	41	59	36	64

Table 2. Relationship between Ki-67 proliferation index in gastric adenocarcinoma (n = 50) to clinico-pathological parameters.

	Tumor grade		Lymphovascular invasion		Neural invasion
Ki-67 proliferation index	Low (Well – Mod)	High (Poor)	+ve	-ve	+ve	-ve
Mod to high n = 35	5	30	21	14	17	18
% age −100	14	86	60	40	49	51
Low n = 15	15	0	1	14	2	13
% age 100	100	0	7	93	14	86

Table 3. Relationship between p-53 mutation status in gastric adenocarcinoma (n = 50) to clinico- pathological parameters.

	Tumor grade		Lymphovascular invasion		Neural invasion
p-53 mutation status	Low (Well – Mod)	High (Poor)	+ve	-ve	+ve	-ve
Focal n = 27	15	12	9	18	8	19
% age −100	56	44	33	67	30	70
Diffuse n = 9	2	7	8	1	7	2
% age 100	22	78	89	11	78	22
Negative n = 14	3	11	5	9	4	10
% age 100	21	79	36	64	29	71

Table 4. Her2-neu expression in gastric adenocarcinoma (n = 50).

Her-2 neu status	Her-2 neu staining intensity	N	% age
Negative	0	43	86*
	1+	1	2
Positive	2+	4	8
	3+	2	4

Her2-neu 1+ (negative)2+ (moderately positive)3+ (strongly positive)

*P ˂0.001 by chi square test.

Table 5. Ki-67 proliferation index p-53 mutation status and in gastric adenocarcinoma (n = 50).

	Ki-67			p-53
	High	Mod	Low	Focal	Diffuse	Negative
N	20	15	15	27	9	14
%age	40	30	30	54	18	28

Table 6. Crosstab showing distribution of p-53 mutation status according to Her2-neu status of gastric adenocarcinoma cases (n = 50).

Her2-neu expression		p-53
		Diffuse	Focal	Negative
Positive (n = 6)	Total (n = 6)	2 (33.33%)*	2 (33.33%)	2 (33.33%)
	2+ (n = 4)	1	1	2
	3+ (n = 2)	1	1	0
Negative (n = 44)	Total (n = 44)	7 (15.91%)	25 (56.81%)*	12 (27.27%)
	+1 (n = 1)	0	1	0
	0 (n = 43)	7	24	12

*: P-value <0.01 on chi square test.

Table 7. Crosstab showing distribution of Ki-67 expression according to Her2-neu status of gastric adenocarcinoma cases (n = 50).

Her2-neu expression		Ki-67
		High	Mod	Low
Positive (n = 6)	Total (n = 6)	5 (83%)*	1 (16.66%)	0 (0%)
	2+ (n = 4)	3	1	0
	3+ (n = 2)	2	0	0
Negative (n = 44)	Total (n = 44)	15 (34%)	14 (31.81%)*	15 (34%)*
	+1 (n = 1)	1	0	0
	0 (n = 43)	14	14	15

*: P-value <0.01 on chi square test.

Figure 1. Her 2 neu ‘3+’ immunoreactivity with its associated high Ki-67 proliferation index and diffuse p-53 mutation status.

(a) Her2 neu3+ (×20); (b) Her2 neu3+ (×40); (c) High Ki-67 (×20); (d) High Ki-67 (×40); (e) Diffuse p-53 (×20); (f) Diffuse p-53 (×40).